IV to Oral Metoprolol Conversion
For acute myocardial infarction, administer 15 mg IV metoprolol (5 mg every 2 minutes × 3 doses), then transition to 50 mg oral every 6 hours starting 15 minutes after the last IV dose, continuing for 48 hours before switching to 100 mg twice daily maintenance dosing. 1, 2
Acute Myocardial Infarction Protocol
The FDA-approved and guideline-endorsed conversion follows this specific algorithm 2:
Initial IV Phase
- Administer 5 mg IV bolus every 2 minutes for 3 doses (total 15 mg) 1, 2
- Monitor blood pressure, heart rate, and ECG continuously during IV administration 2
- This should occur in a coronary care unit once hemodynamic stability is confirmed 2
Transition to Oral Therapy
For patients tolerating full IV dose:
- Start metoprolol tartrate 50 mg orally every 6 hours exactly 15 minutes after the last IV dose 1, 2
- Continue this regimen for 48 hours 2
- Then transition to 100 mg twice daily for maintenance 1
For patients with partial intolerance:
- Start 25-50 mg orally every 6 hours (depending on degree of intolerance) 15 minutes after last IV dose 2
- Adjust based on hemodynamic response 2
For patients with severe intolerance:
- Discontinue metoprolol entirely 2
Critical Contraindications to IV Administration
Do not administer IV metoprolol if any of the following are present 1:
- Signs of heart failure or pulmonary edema
- Systolic blood pressure <120 mmHg
- Heart rate >110 bpm or <60 bpm
- Evidence of low output state or cardiogenic shock risk
- PR interval >0.24 seconds
- Second- or third-degree AV block
- Active asthma or reactive airway disease
Risk Stratification for Cardiogenic Shock
Patients at increased risk (avoid IV beta-blockers) include those with 1:
- Age >70 years
- Systolic BP <120 mmHg
- Sinus tachycardia >110 bpm or bradycardia <60 bpm
- Prolonged time from symptom onset
Pharmacokinetic Considerations
The IV to oral transition is NOT a simple dose equivalence but rather a protocol-driven approach 3, 4:
- IV metoprolol has 100% bioavailability, while oral has approximately 50% bioavailability in extensive metabolizers 2, 5
- The 15 mg IV followed by 200 mg oral daily regimen (50 mg q6h) achieves steady-state plasma concentrations around 200 nmol/L 3
- This dosing maintains therapeutic beta-blockade throughout the critical first 48 hours 3
Special Populations Requiring Dose Adjustment
Hepatic impairment:
- Bioavailability increases to 84% (vs. 50% in normal patients) 5
- Elimination half-life extends to 7.2 hours (vs. 4.2 hours) 5
- Start with lower oral doses and titrate cautiously 2
Renal impairment:
- No dose adjustment required 2
Geriatric patients:
- Use lower initial doses due to decreased hepatic blood flow 2
Evidence Quality and Clinical Context
The COMMIT/CCS-2 trial (45,852 patients) demonstrated that early IV metoprolol reduced reinfarction (OR 0.82) and ventricular fibrillation (OR 0.83) but increased cardiogenic shock (OR 1.30), particularly on days 0-1 4. The excess shock risk was concentrated in hemodynamically unstable patients, while stable patients derived net benefit after day 1 4.
The 2013 ACC/AHA guidelines provide Class IIa recommendation for IV metoprolol administration at presentation in hypertensive patients or those with ongoing ischemia without contraindications 1. The 2017 ESC guidelines similarly support early IV administration in hemodynamically stable patients undergoing primary PCI 1.
Common Pitfalls to Avoid
- Never use a simple dose conversion ratio (e.g., 1:2.5 or 1:5) for metoprolol IV to oral—follow the protocol-driven approach 2, 3
- Do not delay oral dosing beyond 15 minutes after the last IV dose, as this timing is critical for maintaining therapeutic levels 2, 3
- Avoid IV metoprolol in patients with any hemodynamic instability, even if they appear relatively stable—the risk of cardiogenic shock is substantial in the first 24 hours 4
- Do not assume oral absorption is normal post-MI—the first oral dose may have prolonged absorption, but levels stabilize with subsequent dosing 3